```html

Hyperplasia, Endometrial – Comprehensive Medical Guide

Overview

Endometrial hyperplasia is a condition in which the lining of the uterus (the endometrium) becomes thickened due to an over‑growth of the glandular tissue. This thickening is usually a response to excess estrogen without sufficient progesterone to counterbalance it. While many cases are benign, some forms—particularly those described as “atypical” or “complex”—carry an increased risk of progressing to endometrial (uterine) cancer.

Who it affects: The disorder most commonly occurs in women who are:

• Perimenopausal or post‑menopausal (average age 50‑60 years)
• Having irregular menstrual cycles or prolonged periods of estrogen exposure
• Obese (body‑mass index ≥30 kg/m²) – excess fat tissue converts androgens to estrogen
• Using estrogen‑only hormone therapy or tamoxifen

Prevalence: According to the U.S. Centers for Disease Control and Prevention (CDC) and epidemiologic data, endometrial hyperplasia is diagnosed in approximately 5–10 % of women undergoing evaluation for abnormal uterine bleeding, with atypical hyperplasia occurring in about 1–2 % of this group. The condition is far less common in women under 35 years of age.

Symptoms

Symptoms can vary based on the type (simple vs. complex, with or without atypia) and the underlying hormonal milieu. Many women are asymptomatic, and hyperplasia is discovered incidentally during evaluation for other issues.

Typical clinical manifestations

• Abnormal uterine bleeding (AUB): The most frequent sign. Includes heavy or prolonged menstrual bleeding (menorrhagia), bleeding between periods (metrorrhagia), or spotting after menopause.
• Irregular menstrual cycles: Cycles that become shorter (<21 days) or longer (>35 days) without a clear pattern.
• Pelvic pressure or discomfort: Rare, usually when the uterine lining is markedly thickened.
• Post‑coital bleeding: Light spotting after intercourse may occur.

Symptoms that may suggest atypical hyperplasia or progression toward cancer

• Bleeding that occurs after menopause (any bleeding after age 45 should be evaluated).
• Sudden increase in the volume or duration of bleeding.
• Unexplained weight loss, pelvic pain not related to menstruation, or a feeling of fullness in the lower abdomen.

Causes and Risk Factors

Endometrial hyperplasia results from an imbalance between estrogen and progesterone, favoring estrogenic stimulation of the endometrium.

Primary causes

• Unopposed estrogen exposure: Happens when estrogen is present without the protective effect of progesterone. Sources include ovarian estrogen production, obesity‑related aromatization, and certain medications.
• Hormone replacement therapy (HRT): Use of estrogen‑only therapy (especially without added progestin) in post‑menopausal women.
• Polycystic ovary syndrome (PCOS): Chronic anovulation leads to continuous estrogen production.
• Tamoxifen therapy: Used for breast cancer, it has estrogen‑agonist effects on the uterus.

Risk factors that increase the likelihood of developing hyperplasia

• Obesity (BMI ≥30 kg/m²) – higher peripheral conversion of androgens to estrogen.
• Diabetes mellitus – associated with insulin resistance, which can augment estrogen activity.
• Early menarche (<12 years) or late menopause (>55 years) – longer lifetime estrogen exposure.
pro>
• Family history of endometrial or colorectal cancer (possible hereditary non‑polyposis colorectal cancer/Lynch syndrome).
• Nulliparity (never having given birth) – reduces progesterone exposure from pregnancy.
• Use of certain medications: estrogen‑only HRT, tamoxifen, and high‑dose phytoestrogen supplements.

Diagnosis

Because the symptoms overlap with many other gynecologic conditions, a systematic approach is essential.

Initial evaluation

• Detailed medical history & physical exam: Focus on menstrual patterns, medication use, obesity, and risk factors.
• Pap smear: Performed per routine screening; may uncover atypical cells that prompt further work‑up.

Diagnostic tests

• Transvaginal ultrasound (TVUS): First‑line imaging. Measures endometrial thickness; >5 mm in post‑menopausal women or >12 mm in pre‑menopausal women warrants further evaluation.
• Endometrial sampling: Obtained via pipelle biopsy, office curettage, or hysteroscopic directed biopsy. Histopathology determines whether hyperplasia is simple vs. complex and whether atypia is present.
• Hysteroscopy with directed biopsy: Allows direct visualization of the uterine cavity; recommended when ultrasound is inconclusive or when focal lesions are suspected.
• Laboratory tests: Thyroid function, fasting glucose, and hormone panels (estradiol, progesterone) may help identify underlying endocrine disorders.
• MRI (rarely needed): Reserved for cases where extensive myometrial invasion is suspected.

Diagnosis is confirmed when pathology reports indicate proliferation of endometrial glands, with or without cellular atypia.

Treatment Options

Treatment is tailored to the type of hyperplasia, desire for future fertility, age, and presence of risk factors.

Medical management

• Progestin therapy: First‑line for most women.
  • Oral micronized progesterone (200 mg daily) or medroxyprogesterone acetate (10–20 mg daily) for 3–6 months.
  • High‑dose levonorgestrel‑releasing intrauterine system (LNG‑IUS, e.g., Mirena) provides continuous local progestin with <90 % remission rates for simple hyperplasia.
• Metformin: Beneficial in women with PCOS or insulin resistance; improves progesterone responsiveness.
• Weight loss interventions: Dietary modification and structured exercise can reduce peripheral estrogen production.

Surgical options

• Hysteroscopic resection: Removes focal hyperplastic lesions while preserving the uterus; considered when medical therapy fails.
• Endometrial ablation: Destroys the lining; appropriate for women who have completed childbearing and have non‑atypical hyperplasia.
• Hysterectomy: Definitive treatment, recommended for:
  • Complex atypical hyperplasia in women who no longer desire fertility.
  • Failure of progestin therapy after 6–12 months.
  • Concurrent diagnosis of endometrial carcinoma.

Follow‑up care

After successful treatment, repeat endometrial sampling is usually performed 3–6 months later, then annually for at least 2–5 years, especially in women with atypia or ongoing risk factors.

Living with Hyperplasia, Endometrial

Managing the condition goes beyond medication. Below are practical suggestions for everyday life.

• Maintain a healthy weight: Aim for a BMI < 25 kg/m². Even modest weight loss (5‑10 % of body weight) can lower estrogen levels.
• Balanced diet: Emphasize fiber‑rich vegetables, fruits, whole grains, and lean protein. Limit red meat, processed foods, and high‑sugar drinks.
• Regular physical activity: At least 150 minutes of moderate aerobic exercise per week (e.g., brisk walking, cycling).
• Medication adherence: Take progestins exactly as prescribed. Set reminders or use a pill organizer.
• Track menstrual patterns: Use a diary or a tracking app to note flow, spotting, and cycle length; report changes promptly.
• Manage comorbidities: Keep diabetes, hypertension, and thyroid disease well‑controlled.
• Limit estrogen‑rich supplements: Discuss any over‑the‑counter herbs (e.g., soy isoflavones) with your provider.
• Psychosocial support: Anxiety about cancer risk is common; consider counseling or support groups.

Prevention

While not all cases are preventable, risk can be substantially reduced.

• Achieve and sustain a healthy weight through diet and exercise.
• Use combined estrogen‑progestin HRT rather than estrogen‑only therapy if menopause symptoms require treatment.
• Limit long‑term tamoxifen use when alternatives exist; discuss regular uterine monitoring with your oncologist.
• Screen and treat PCOS early; incorporate metformin and lifestyle changes.
• Stay current with routine gynecologic exams, especially if you have risk factors.

Complications

If left untreated or inadequately managed, endometrial hyperplasia can lead to serious outcomes.

• Progression to endometrial carcinoma: Atypical hyperplasia carries a 5‑30 % risk of developing cancer within 5 years (average 16 % per Mayo Clinic data).
• Severe anemia: Chronic heavy bleeding may cause iron‑deficiency anemia, leading to fatigue, shortness of breath, and reduced quality of life.
• Infertility: Disordered endometrial development can interfere with implantation.
• Recurrent abnormal bleeding: May require repeated interventions, increasing surgical risk.

When to Seek Emergency Care

References

• Mayo Clinic. “Endometrial hyperplasia.” https://www.mayoclinic.org
• American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 194: “Endometrial Hyperplasia.” 2018.
• National Cancer Institute. “Endometrial Cancer Prevention (PDQ®)–Patient Version.” Updated 2023.
• World Health Organization. “Obesity and Cancer.” 2022 Fact Sheet.
• Cleveland Clinic. “Endometrial Hyperplasia: Symptoms, Diagnosis, and Treatment.” 2024.
• Centers for Disease Control and Prevention (CDC). “Uterine Cancer Statistics.” 2023.

```